12,872 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,872 shares of the biopharmaceutical company’s stock, valued at approximately $944,000.

A number of other large investors have also recently bought and sold shares of HALO. EverSource Wealth Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the period. Brown Advisory Inc. increased its holdings in Halozyme Therapeutics by 0.6% in the second quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock worth $1,824,000 after purchasing an additional 224 shares in the last quarter. VELA Investment Management LLC increased its holdings in Halozyme Therapeutics by 2.0% in the second quarter. VELA Investment Management LLC now owns 12,989 shares of the biopharmaceutical company’s stock worth $676,000 after purchasing an additional 260 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its stake in Halozyme Therapeutics by 0.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,473 shares of the biopharmaceutical company’s stock valued at $2,209,000 after buying an additional 384 shares during the period. Finally, Cetera Trust Company N.A boosted its holdings in shares of Halozyme Therapeutics by 7.4% during the 2nd quarter. Cetera Trust Company N.A now owns 6,200 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 425 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 0.7%

Shares of NASDAQ HALO opened at $68.87 on Monday. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. The company has a 50-day moving average price of $67.34 and a 200-day moving average price of $65.57. The stock has a market capitalization of $8.10 billion, a P/E ratio of 14.50, a P/E/G ratio of 0.37 and a beta of 0.95. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.27 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total transaction of $59,356.40. Following the transaction, the director owned 42,123 shares of the company’s stock, valued at $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Cortney Caudill sold 4,263 shares of the company’s stock in a transaction on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total value of $277,904.97. Following the sale, the chief operating officer owned 12,737 shares of the company’s stock, valued at $830,325.03. This trade represents a 25.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 85,661 shares of company stock valued at $6,036,837 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on HALO shares. Benchmark lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $75.10.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.